thymine has been researched along with Local Neoplasm Recurrence in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)." | 8.12 | Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 7.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
| "TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer." | 5.34 | TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. ( Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D, 2020) |
| "For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival." | 4.12 | Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022) |
| "Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)." | 4.12 | Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022) |
| "Trifluridine/tipiracil (TAS-102) is an important chemotherapeutic agent recommended by the Japanese guidelines as third- or fourth-line treatment for colorectal cancer." | 4.02 | [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab]. ( Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A, 2021) |
| "Trifluridine/tipiracil (FTD/TPI) improves the overall survival (OS) of metastatic colorectal cancer (mCRC) patients." | 3.96 | Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. ( Hata, T; Kagawa, Y; Kato, T; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2020) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 3.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
| "The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated." | 3.85 | Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer ( Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2017) |
| " Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95." | 1.43 | Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 8 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Jalali, A | 1 |
| Gard, G | 1 |
| Banks, S | 1 |
| Dunn, C | 1 |
| Wong, HL | 1 |
| Wong, R | 1 |
| Lee, M | 1 |
| Gately, L | 1 |
| Loft, M | 1 |
| Shapiro, JD | 1 |
| Kosmider, S | 1 |
| Tie, J | 1 |
| Ananda, S | 1 |
| Yeung, JM | 1 |
| Jennens, R | 1 |
| Lee, B | 1 |
| McKendrick, J | 1 |
| Lim, L | 1 |
| Khattak, A | 1 |
| Gibbs, P | 1 |
| Oshima, K | 1 |
| Hirano, H | 1 |
| Shoji, H | 1 |
| Iwasa, S | 1 |
| Okita, N | 1 |
| Takashima, A | 1 |
| Boku, N | 1 |
| Pfeiffer, P | 1 |
| Yilmaz, M | 1 |
| Möller, S | 1 |
| Zitnjak, D | 1 |
| Krogh, M | 1 |
| Petersen, LN | 1 |
| Poulsen, LØ | 1 |
| Winther, SB | 1 |
| Thomsen, KG | 1 |
| Qvortrup, C | 1 |
| Nose, Y | 1 |
| Kagawa, Y | 1 |
| Hata, T | 1 |
| Mori, R | 1 |
| Kawai, K | 1 |
| Naito, A | 2 |
| Sakamoto, T | 1 |
| Murakami, K | 1 |
| Katsura, Y | 1 |
| Ohmura, Y | 1 |
| Masuzawa, T | 1 |
| Takeno, A | 1 |
| Takeda, Y | 1 |
| Kato, T | 2 |
| Murata, K | 1 |
| Hamada, S | 1 |
| Komatsu, S | 1 |
| Shibata, R | 1 |
| Konishi, T | 1 |
| Matsubara, D | 1 |
| Soga, K | 1 |
| Shimomura, K | 1 |
| Ikeda, J | 1 |
| Taniguchi, F | 1 |
| Shioaki, Y | 1 |
| Iwamoto, K | 1 |
| Ohtsuka, M | 1 |
| Imasato, M | 1 |
| Inui, M | 1 |
| Zenitani, S | 1 |
| Wada, R | 1 |
| Nakahara, Y | 1 |
| Mikamori, M | 1 |
| Furukawa, K | 1 |
| Moon, J | 1 |
| Asaoka, T | 1 |
| Kishi, K | 1 |
| Akamatsu, H | 1 |
| Maeda, F | 1 |
| Gan, S | 1 |
| Yamada, A | 1 |
| Kajiyama, D | 1 |
| Tokitou, F | 1 |
| Kawaguchi, M | 1 |
| Amagasa, H | 1 |
| Motoyama, K | 1 |
| Ganno, H | 1 |
| Imai, K | 1 |
| Ami, K | 1 |
| Iida, S | 1 |
| Fukuda, A | 1 |
| Ando, M | 1 |
| Okano, Y | 1 |
| Taniguchi, H | 1 |
| Nakamura, Y | 1 |
| Kotani, D | 1 |
| Yukami, H | 1 |
| Mishima, S | 1 |
| Sawada, K | 1 |
| Shirasu, H | 1 |
| Ebi, H | 1 |
| Yamanaka, T | 1 |
| Aleshin, A | 1 |
| Billings, PR | 1 |
| Rabinowitz, M | 1 |
| Oki, E | 1 |
| Takemasa, I | 1 |
| Mori, M | 1 |
| Yoshino, T | 1 |
| Kimura, M | 4 |
| Usami, E | 4 |
| Iwai, M | 3 |
| Teramachi, H | 3 |
| Yoshimura, T | 4 |
| Arnold, D | 1 |
| Prager, GW | 1 |
| Quintela, A | 1 |
| Stein, A | 1 |
| Moreno Vera, S | 1 |
| Mounedji, N | 1 |
| Taieb, J | 1 |
| Yasue, F | 1 |
| Kawachi, S | 1 |
| Mitsuoka, M | 1 |
| Ikeda, Y | 1 |
| Goldberg, R | 1 |
| Go, M | 1 |
| Ito, D | 1 |
| Asano, H | 1 |
| Saito, T | 1 |
| Mitomi, H | 1 |
| Izumi, H | 1 |
| Suehara, Y | 1 |
| Okubo, T | 1 |
| Torigoe, T | 1 |
| Takagi, T | 1 |
| Kaneko, K | 1 |
| Sato, K | 1 |
| Matsumoto, T | 1 |
| Yao, T | 1 |
| Eshghyar, N | 1 |
| Nikbin, B | 1 |
| Amirzargar, A | 1 |
| Dehghani Nazhvani, A | 1 |
| Shakiba, Y | 1 |
| Kämmerer, PW | 1 |
| Koch, FP | 1 |
| Schiegnitz, E | 1 |
| Kumar, VV | 1 |
| Berres, M | 1 |
| Toyoshima, T | 1 |
| Al-Nawas, B | 1 |
| Brieger, J | 1 |
| Vashist, YK | 1 |
| Blessmann, M | 1 |
| Trump, F | 1 |
| Kalinin, V | 1 |
| Kutup, A | 1 |
| Schneider, C | 1 |
| Gawad, K | 1 |
| Kaifi, JT | 1 |
| Schmelzle, R | 1 |
| Izbicki, JR | 1 |
| Yekebas, EF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981] | Phase 2 | 136 participants (Anticipated) | Interventional | 2020-09-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thymine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neopla | 2018 |
2 trials available for thymine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combin | 2020 |
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Circulating Tu | 2021 |
15 other studies available for thymine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm | 2022 |
Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2020 |
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neo | 2020 |
[Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2020 |
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2021 |
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans; | 2018 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2016 |
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; | 2016 |
A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up.
Topics: Adenocarcinoma; Arthrography; Base Sequence; Cell Transformation, Neoplastic; Cysteine; Femur; Fibro | 2011 |
Gene polymorphism of interleukin-1 alpha and beta in keratocystic odontogenic tumors.
Topics: Adolescent; Adult; Aged; Alleles; Case-Control Studies; Child; Cytosine; Epithelial Cells; Female; F | 2012 |
Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cytosine; Disease-Free Survival | 2013 |
Microsatellite GTn-repeat polymorphism in the promoter of heme oxygenase-1 gene is an independent predictor of tumor recurrence in male oral squamous cell carcinoma patients.
Topics: Alleles; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Forecasting; Ge | 2008 |